XMT-1660: A Phase 1b trial of a B7-H4 targeting antibody drug conjugate (ADC) in endometrial, ovarian, and breast cancers

被引：0
|
作者：
Hamilton, Erika [1 ]
Spira, Alexander [2 ]
Adams, Sylvia [3 ]
Abuhadra, Nour [4 ]
Giordano, Antonio [5 ]
Parajuli, Ritesh [6 ]
Han, Hyo [7 ]
Weise, Amy [8 ]
Marchesani, Aubri [9 ]
Josephs, Kate [9 ]
Chaudhry, Arvind [10 ]
Kalinsky, Kevin [11 ]
机构：
[1] Sarah Cannon Res Inst, Nashville, TN USA
[2] NEXT Oncol, Fairfax, VA USA
[3] NYU Langhone, Perlmutter Canc Ctr, New York, NY USA
[4] Mem Sloan Kettering Canc Ctr, New York, NY USA
[5] Dana Farber Canc Inst, Boston, MA USA
[6] Univ Calif Irvine, Chao Family Comprehens Canc Ctr, Irvine, CA USA
[7] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[8] Henry Ford Canc Inst, Detroit, MI USA
[9] Mersana Therapeut, Cambridge, MA USA
[10] Summit Canc Ctr, Spokane, WA USA
[11] Winship Canc Inst, Atlanta, GA USA
来源：
GYNECOLOGIC ONCOLOGY | 2023年 / 176卷
关键词：
D O I：
10.1016/j.ygyno.2023.06.159
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1250
引用
收藏
页码：S158 / S158
页数：1
相关论文
共 50 条
  • [21] HER2-targeting antibody drug conjugate FS-1502 in HER2-expressing metastatic breast cancer: a phase 1a/1b trial
    Li, Qiao
    Cheng, Ying
    Tong, Zhongsheng
    Liu, Yunjiang
    Wang, Xian
    Yan, Min
    Chang, Jianhua
    Wang, Shusen
    Du, Caiwen
    Li, Liang
    Wu, Chunjiao
    Wang, Mingxia
    Wang, Zhuo
    Wu, Zhuli
    Wang, Xingli
    Jin, Yongli
    Diao, Lei
    Sun, Yi
    Zhang, Yongjiao
    Hui, Ai-Min
    Xu, Binghe
    NATURE COMMUNICATIONS, 2024, 15 (01)
  • [22] SGN-B7H4V, A NOVEL, INVESTIGATIONAL VEDOTIN ANTIBODY-DRUG CONJUGATE DIRECTED TO THE T CELL CHECKPOINT LIGAND B7-H4, SHOWS PROMISING
    Gray, Elizabeth
    Epp, Angela
    Ulrich, Michelle
    Sahetya, Disha
    Hensley, Kelly
    Hahn, Julie
    Allred, Sean
    Haass, Jane
    Snead, Katie
    Lucas, Sasha
    Gosink, John
    Boyce, Rogely
    Trueblood, Esther
    Treuting, Piper
    Frantz, Chris
    Smith, Alyson
    Schrum, Jason
    Nazarenko, Natalya
    Gardai, Shyra
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A895 - A895
  • [23] Updated Results from the Phase 1 Expansion Study of Upifitamab Rilsodotin (UpRi; XMT-1536), a NaPi2b-directed Dolaflexin Antibody Drug Conjugate (ADC) in Ovarian Cancer
    Richardson, Debra
    Hamilton, Erika
    Barve, Minal
    Anderson, Charles
    Taylor, Sara
    Lakhani, Nehal
    Buscema, Joseph
    Tolcher, Anthony
    Zarwan, Corrine
    Werner, Theresa
    Hays, John
    Arend, Rebecca
    Edenfield, Jeffery
    Putiri, Emily
    Bernardo, Patricia
    Burger, Robert
    Matulonis, Ursula
    GYNECOLOGIC ONCOLOGY, 2022, 166 : S48 - S48
  • [24] Phase 1a/1b study of first-in-class B7-H4 antibody, FPA150, as monotherapy in patients with advanced solid tumors.
    Sachdev, Jasgit C.
    Bauer, Todd Michael
    Chawla, Sant P.
    Pant, Shubham
    Patnaik, Amita
    Wainberg, Zev A.
    Inamdar, Sandeep P.
    Marina, Neyssa
    Sun, Stefanie
    Schmidt, Maike
    Xiang, Hong
    LoRusso, Patricia
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [25] Results from the phase 1 dose escalation study of XMT-1592, a dolasynthen NAPI2B-directed antibody-drug conjugate (ADC)
    Hamilton, Erika P.
    Papadopoulos, Kyriakos P.
    Barve, Minal
    Lakhani, Nehal
    Burns, Timothy F.
    Burger, Robert A.
    Reske, Adi
    Wekheye, Kelley
    Tolcher, Anthony
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2024, 34 (SUPPL_1) : A343 - A343
  • [26] Phase 1a/1b study of FOR46, an antibody drug conjugate (ADC), targeting CD46 in metastatic castration-resistant prostate cancer (mCRPC)
    Aggarwal, Rahul Raj
    Vuky, Jacqueline
    VanderWeele, David James
    Rettig, Matthew
    Heath, Elisabeth I.
    Beer, Tomasz M.
    Huang, Jiaoti
    Pawlowska, Nela
    Sinit, Ryan
    Abbey, Jill
    Liu, Bin
    Nasoff, Marc
    Dorr, Andrew
    Small, Eric Jay
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [27] Relationship of NaPi2b expression and efficacy of XMT-1536, a NaPi2b targeting antibody-drug conjugate (ADC), in an unselected panel of human primary ovarian mouse xenograft models
    Mosher, Rebecca
    Poling, Laura
    Qin, LiuLiang
    Bodyak, Natalya
    Bergstrom, Donald
    MOLECULAR CANCER THERAPEUTICS, 2018, 17 (01)
  • [28] Phase 1 dose escalation study of XMT-1536, a novel NaPi2b-targeting antibody-drug conjugate (ADC), in patients (pts) with solid tumors likely to express NaPi2b.
    Tolcher, Anthony W.
    Ulahannan, Susanna Varkey
    Papadopoulos, Kyriakos P.
    Edenfield, William Jeffery
    Matulonis, Ursula A.
    Burns, Timothy F.
    Mosher, Rebecca
    Fielman, Barbara
    Hailman, Eric
    Burris, Howard A.
    Moore, Kathleen N.
    Hamilton, Erika Paige
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [29] LNCB74 is a potent and safe next-generation antibody-drug-conjugate utilizing a cancer selective linker for the treatment of B7-H4 expressing cancers
    Fitzgerald, Daniel P.
    Doan, Duc N.
    Peacock, Riley B.
    Kahan, Shannon M.
    Lomash, Suvendu
    Slocum, Stephen
    Jung, Kwang Hwa
    Oh, Hwanhee
    Meza, Ingrid
    Manzanarez, Yanira
    Selvam, Shanmugam
    Flies, Dallas B.
    Chung, Chul-Woong
    Langermann, Sol
    CANCER RESEARCH, 2024, 84 (06)
  • [30] First-in-human/phase I trial of HS-20089, a B7-H4 ADC, in patients with advanced solid tumors
    Wu, J.
    Zhang, J.
    Li, H.
    Wang, X.
    Zhang, Q. Y.
    Shi, Y.
    Yan, M.
    Pan, Y.
    Shen, A.
    Chen, Q.
    Rao, Q.
    Wei, H.
    Li, C.
    Yang, L.
    Huang, Q.
    Cao, Z.
    Wu, Q.
    ANNALS OF ONCOLOGY, 2023, 34 : S336 - S336
12345